The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Cholinesterase Inhibitors: A New Class of Psychotropic Compounds
Abstract
OBJECTIVE: This article reviews evidence indicating that acetylcholinesterase inhibitors have psychotropic properties. METHOD: The author reviewed the English-language literature pertinent to the response of neuropsychiatric symptoms in Alzheimer's disease and related conditions to cholinergic agents. RESULTS: The cholinergic system originates in the basal forebrain and projects diffusely to the cerebral cortex; the limbic and paralimbic regions receive the most abundant cholinergic projections. The basal forebrain nuclei are positioned at the interface of the limbic system and cerebral cortex, where they play a role in mediating emotional responses. The basal forebrain nuclei are atrophic in Alzheimer's disease, leading to a widespread cholinergic deficit. The cholinergic disturbance may contribute to neuropsychiatric manifestations of the disease. The treatment of patients with Alzheimer's disease with acetylcholinesterase inhibitors reduces neuropsychiatric symptoms, particularly apathy and visual hallucinations. In some studies, a variety of other neuropsychiatric symptoms have been reported to respond to treatment with acetylcholinesterase inhibitors. Response profiles vary among acetylcholinesterase inhibitors. CONCLUSIONS: Acetylcholinesterase inhibitors have psychotropic effects and may play an important role in controlling neuropsychiatric and behavioral disturbances in patients with Alzheimer's disease. These agents also may contribute to the management of other disorders with cholinergic system abnormalities and neuropsychiatric symptoms. The beneficial response is most likely mediated through limbic cholinergic structures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Self-citationA new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
(1987) · PubMed · Cited by 1,147
Knapp, M. J. (1994) · JAMA · doi:10.1001/jama.271.13.985 · Cited by 1,004
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Rogers, S. L. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.9.1021 · Cited by 773
Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.8.1049 · Cited by 744
Rogers, S. L., & Friedhoff, L. T. (1996) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106895 · Cited by 742
Bodick, N. C., Offen, W. W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., Shannon, H. E., Tollefson, G. D., Rasmussen, K., Bymaster, F. P., et al. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550160091022 · Cited by 692
A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease
Davis, K. L., Thal, L. J., Gamzu, E. R., Davis, C. S., Woolson, R. F., Gracon, S. I., Drachman, D. A., Schneider, L. S., Whitehouse, P. J., Hoover, T. M., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210293271801 · Cited by 626
Kaufer, D. I., Cummings, J. L., Christine, D., Bray, T., Castellon, S., Masterman, D., MacMillan, A., Ketchel, P., & DeKosky, S. T. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb02542.x · Cited by 606
Self-citationPoirier, J., Delisle, M. C., Quirion, R., Aubert, I., Farlow, M., Lahiri, D., Hui, S., Bertrand, P., Nalbantoglu, J., & Gilfix, B. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.26.12260 · Cited by 595
Basal forebrain neurons in the dementia of Parkinson disease
Whitehouse, P. J., Hedreen, J. C., White, C. L., & Price, D. L. (1983) · Annals of Neurology · doi:10.1002/ana.410130304 · Cited by 534
Decker, M. W., & McGaugh, J. L. (1991) · Synapse · doi:10.1002/syn.890070209 · Cited by 524
Cholinergic Markers in Elderly Patients With Early Signs of Alzheimer Disease
Davis, K. L. (1999) · JAMA · doi:10.1001/jama.281.15.1401 · Cited by 492
Corey-Bloom, J. (1998) · Medical Entomology and Zoology · Cited by 467
Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain
McGeer, P. L., McGeer, E. G., Suzuki, J., Dolman, C. E., & Nagai, T. (1984) · Neurology · doi:10.1212/wnl.34.6.741 · Cited by 457
Cholinergic Switching Within Neocortical Inhibitory Networks
Xiang, Z., Huguenard, J. R., & Prince, D. A. (1998) · Science · doi:10.1126/science.281.5379.985 · Cited by 438
A Controlled Trial of Tacrine in Alzheimer's Disease
Farlow, M. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03490180055026 · Cited by 398
NEURAL INPUTS INTO THE NUCLEUS BASALIS OF THE SUBSTANTIA INNOMINATA (Ch4) IN THE RHESUS MONKEY
MESULAM, M.-M., & MUFSON, E. J. (1984) · Brain · doi:10.1093/brain/107.1.253 · Cited by 316
Intravenous nicotine in Alzheimer's disease: a pilot study
Newhouse, P. A., Sunderland, T., Tariot, P. N., Blumhardt, C. L., Weingartner, H., Mellow, A., & Murphy, D. L. (1988) · Psychopharmacology · doi:10.1007/bf00174504 · Cited by 308
Shader, R. I., Harmatz, J. S., & Salzman, C. (1974) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1974.tb01521.x · Cited by 306
Sunderland, T. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800170032006 · Cited by 298
Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
Morris, J. C., Cyrus, P. A., Orazem, J., Mas, J., Bieber, F., Ruzicka, B. B., & Gulanski, B. (1998) · Neurology · doi:10.1212/wnl.50.5.1222 · Cited by 287
COOPER, J. A., SAGAR, H. J., DOHERTY, S. M., JORDAN, N., TIDSWELL, P., & SULLIVAN, E. V. (1992) · Brain · doi:10.1093/brain/115.6.1701 · Cited by 275
The Cholinergic Hypothesis of Neuropsychiatric Symptoms in Alzheimer's Disease
Cummings, J. L., & Back, C. (1998) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-199821001-00009 · Cited by 274
Self-citationNeuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited
Cummings, J. L., & Kaufer, D. (1996) · Neurology · doi:10.1212/wnl.47.4.876 · Cited by 251
Self-citationEffects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease
Schneider, L. S., Farlow, M. R., Henderson, V. W., & Pogoda, J. M. (1996) · Neurology · doi:10.1212/wnl.46.6.1580 · Cited by 250
The Spectrum of Behavioral Responses to Cholinesterase Inhibitor Therapy in Alzheimer Disease
Mega, M. S., Masterman, D. M., O'Connor, S. M., Barclay, T. R., & Cummings, J. L. (1999) · Archives of Neurology · doi:10.1001/archneur.56.11.1388 · Cited by 236
Self-citationDifferential Regulation of Molecular Subtypes of Muscarinic Receptors in Alzheimer's Disease
Flynn, D. D., Ferrari‐DiLeo, G., Mash, D. C., & Levey, A. I. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64041888.x · Cited by 234
Long‐term acetyl‐L‐carnitine treatment in Alzheimer's disease
Spagnoli, A., Lucca, U., Menasce, G., Bandera, L., Cizza, G., Forloni, G., Tettamanti, M., Frattura, L., Tiraboschi, P., Comelli, M., et al. (1991) · Neurology · doi:10.1212/wnl.41.11.1726 · Cited by 232
Donepezil for Treatment of Dementia With Lewy Bodies: A Case Series of Nine Patients
Shea, C., MacKnight, C., & Rockwood, K. (1998) · International Psychogeriatrics · doi:10.1017/s1041610298005341 · Cited by 229
Conformation gating as a mechanism for enzyme specificity
Zhou, H.-X., Wlodek, S. T., & McCammon, J. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9280 · Cited by 221
Knopman, D. S., Knapp, M. J., Gracon, S. I., & Davis, C. S. (1994) · Neurology · doi:10.1212/wnl.44.12.2315 · Cited by 213
Effect of Tacrine on Behavioral Symptoms in Alzheimer's Disease: An Open-Label Study
Kaufer, D. I., Cummings, J. L., & Christine, D. (1996) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879600900101 · Cited by 206
Self-citationThe nucleus basalis of Meynert in neurological disease: A quantitative morphological study
Rogers, J. D., Brogan, D., & Mirra, S. S. (1985) · Annals of Neurology · doi:10.1002/ana.410170210 · Cited by 200
Farlow, M. R., Lahiri, D. K., Poirier, J., Davignon, J., Schneider, L., & Hui, S. L. (1998) · Neurology · doi:10.1212/wnl.50.3.669 · Cited by 199
Geula, C. (1998) · Neurology · doi:10.1212/wnl.51.1_suppl_1.s18 · Cited by 184
Metrifonate treatment of the cognitive deficits of Alzheimer's disease
Cummings, J. L., Cyrus, P. A., Bieber, F., Mas, J., Orazem, J., Gulanski, B., & The Metrifonate Study Group* (1998) · Neurology · doi:10.1212/wnl.50.5.1214 · Cited by 172
Self-citationAlzheimer Disease, Attention, and the Cholinergic System
Lawrence, A. D., & Sahakian, B. J. (1995) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199501002-00008 · Cited by 167
Cholinesterase Inhibition for Alzheimer Disease: A Meta-analysis of the Tacrine Trials
Qizilbash, N., Whitehead, A., Higgins, J., Wilcock, G., Schneider, L., Farlow, M., & for the Dementia Trialists' Collaboration (1998) · JAMA · doi:10.1001/jama.280.20.1777 · Cited by 161
Cholinesterase inhibition in Parkinson's disease.
Hutchinson, M., & Fazzini, E. P. (1996) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.61.3.324-a · Cited by 150
Cholinergic Receptors in Cognitive Disorders
Perry, E. K., Perry, R. H., Smith, C. J., Purohit, D. P., Bonham, J. R., Dick, D. J., Candy, J., Edwardson, J. A., & FAIRBAIRN, A. F. (1986) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100037240 · Cited by 149
Fishman, E. B., Siek, G. C., MacCallum, R. D., Bird, E. D., Volicer, L., & Marquis, J. K. (1986) · Annals of Neurology · doi:10.1002/ana.410190305 · Cited by 146
Rodríguez‐Puertas, R., Pascual, J., Vilaró, M. T., & Pazos, Á. (1997) · Synapse · doi:10.1002/(sici)1098-2396(199708)26:4<341::aid-syn2>3.0.co;2-6 · Cited by 125
Cholinergic deficiency and frontal dysfunction in Parkinson's disease
Dubois, B., Pillon, B., Lhermitte, F., & Agid, Y. (1990) · Annals of Neurology · doi:10.1002/ana.410280202 · Cited by 125
Physostigmine ameliorates the delusions of Alzheimer's disease
Cummings, J. L., Gorman, D. G., & Shapira, J. S. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90009-3 · Cited by 123
Self-citationCortical Cholinergic Dysfunction After Human Head Injury
MURDOCH, I., PERRY, E. K., COURT, J. A., GRAHAM, D. I., & DEWAR, D. (1998) · Journal of Neurotrauma · doi:10.1089/neu.1998.15.295 · Cited by 121
Induction of depression with oxotremorine in patients with Alzheimer's disease
Davis, K. L., Hollander, E., Davidson, M., Davis, B. J., Mohs, R. C., & Horvath, T. (1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.4.468 · Cited by 113
Effect of Tacrine on Language, Praxis, and Noncognitive Behavioral Problems in Alzheimer Disease
Raskind, M. A., Sadowsky, C. H., Sigmund, W. R., Beitler, P., & Auster, S. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550190026010 · Cited by 111
Dementia with Lewy bodies: Response of delirium-like features to donepezil
Kaufer, D., Catt, K. E., López, O. L., & DeKosky, S. T. (1998) · Neurology · doi:10.1212/wnl.51.5.1512 · Cited by 111
Rasool, C. G., Svendsen, C. N., & Selkoe, D. J. (1986) · Annals of Neurology · doi:10.1002/ana.410200407 · Cited by 106
Multiple-Dose Arecoline Infusions in Alzheimer's Disease
Tariot, P. N., Cohen, R. M., Welkowitz, J. A., Sunderland, T., Newhouse, P. A., Murphy, D. L., & Weingartner, H. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800340023003 · Cited by 105
Raskind, M. A., Cyrus, P. A., Ruzicka, B. B., et al. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0510 · Cited by 99
An economic evaluation of donepezil in the treatment of Alzheimer's disease
Small, G. W., Donohue, J. A., & Brooks, R. L. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80145-8 · Cited by 95
Neuron loss in the nucleus basalis of meynert in parkinsonism‐dementia complex of Guam
Nakano, I., & Hirano, A. (1983) · Annals of Neurology · doi:10.1002/ana.410130118 · Cited by 91
Allen, S. J., MacGowan, S. H., Tyler, S., Wilcock, G., Robertson, A., Holden, P., Smith, S. K. F., & Dawbarn, D. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00872-0 · Cited by 89
Becker, R. E., Colliver, J. A., Elble, R. J., et al. (1990) · Drug Development Research · doi:10.1002/ddr.430190407 · Cited by 89
THE ROLE OF THE NUCLEUS BASALIS OF MEYNERT IN DEMENTIA: REVIEW AND RECONSIDERATION
Cummnings, J. L., & Benson, D. F. (1987) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198701030-00003 · Cited by 88
Schizophrenia and Alzheimer's disease: Clinical and pathophysiologic analogies
White, K. E., & Cummings, J. L. (1996) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(96)90035-8 · Cited by 85
Self-citationDonepezil for dementia with Lewy bodies: a case study
Aarsland, D., Brønnick, K., & Karlsen, K. (1999) · International Journal of Geriatric Psychiatry · Cited by 85
Intraventricular bethanechol infusion for Alzheimer's disease
Penn, R. D., Martin, E. M., Wilson, R. S., Fox, J. H., & Savoy, S. M. (1988) · Neurology · doi:10.1212/wnl.38.2.219 · Cited by 78
Donepezil in treatment-resistant bipolar disorder
Burt, T., Sachs, G. S., & Demopulos, C. M. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00320-5 · Cited by 75
Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease
Sramek, J. J., Anand, R., Wardle, T. S., Irwin, P., Hartman, R. D., & Cutler, N. R. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00081-1 · Cited by 75
A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer’s disease
Thal, L. J., Ferguson, J. M., Mintzer, J. E., Raskin, A., & Targum, S. D. (1999) · Neurology · doi:10.1212/wnl.52.6.1146 · Cited by 72
Kaufer, D., Cummings, J. L., & Christine, D. (1998) · Journal of Neuropsychiatry · doi:10.1176/jnp.10.1.55 · Cited by 70
Self-citationDevelopment of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease
Taylor, P. (1998) · Neurology · doi:10.1212/wnl.51.1_suppl_1.s30 · Cited by 69
Proteins, Transmitters and Synapses
Nicholls, D. G. (1994) · Medical Entomology and Zoology · Cited by 67
Molecular forms of acetylcholinesterases in Alzheimer's disease.
Sg, Y., Goodridge, B., Katz, J., Lockett, G., Nafziger, D., Usiak, M., & Younkin, L. H. (1986) · PubMed · Cited by 63
Pick's disease (lobar sclerosis)
Uhl, G. R., Hilt, D. C., Hedreen, J. C., Whitehouse, P. J., & Price, D. L. (1983) · Neurology · doi:10.1212/wnl.33.11.1470 · Cited by 62
Neuronal loss in the basal nucleus of meynert in progressive supranuclear palsy
Tagliavini, F., Pilleri, G., Gemignani, F., & Lechi, A. (1983) · Acta Neuropathologica · doi:10.1007/bf00697397 · Cited by 60
Effectiveness and Safety of Velnacrine for the Treatment of Alzheimer's Disease
Antuono, P. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430160102010 · Cited by 58
Use of Donepezil for Vascular Dementia
Mendez, M. F., Younesi, F. L., & Perryman, K. M. (1999) · Journal of Neuropsychiatry · doi:10.1176/jnp.11.2.268 · Cited by 57
Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer’s disease
Imbimbo, B. P., Martelli, P. R., Troetel, W. M., Lucchelli, F., Lucca, U., Thal, L. J., & The Eptastigmine Study Group (1999) · Neurology · doi:10.1212/wnl.52.4.700 · Cited by 53
Perry, E. K., Kerwin, J. M., Perry, R. H., Irving, D., Blessed, G., & FAIRBAIRN, A. F. (1990) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000107114 · Cited by 52
Galanthamine in Alzheimer??s Disease
Rainer, M. K. (1997) · CNS Drugs · doi:10.2165/00023210-199707020-00001 · Cited by 50
Salehi, A., Martinez, V., & Swaab, D. F. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00106-7 · Cited by 40
Soluble and membrane-bound forms of brain acetylcholinesterase in Alzheimer's disease.
Schegg, K., Harrington, L., Neilsen, S., Zweig, R., & Peacock, J. (1992) · Neurobiology of Aging · doi:10.1016/0197-4580(92)90092-c · Cited by 35
Mechanisms of cell death in cholinergic basal forebrain neurons in chronic alcoholics
Cullen, K. M., & Halliday, G. M. (1995) · Metabolic Brain Disease · doi:10.1007/bf01991785 · Cited by 31
MOLECULAR FORMS OF ACETYLCHOLINESTERASE IN ALZHEIMERʼS DISEASE
Younkin, L. H., Lockett, G., Usiak, M., Younkin, S. G., & Roessmann, U. (1986) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-198605000-00190 · Cited by 29
Impaired cognitive shifting in parkinsonian patients on anticholinergic therapy
van Spaendonck, K. P. M., Berger, H. J. C., Horstink, M. W. I. M., Buytenhuijs, E. L., & Cools, A. R. (1993) · Neuropsychologia · doi:10.1016/0028-3932(93)90164-u · Cited by 29
Neuronal loss in the basal nucleus of Meynert in a patient with olivopontocerebellar atrophy
Tagliavini, F., & Pilleri, G. (1985) · Acta Neuropathologica · doi:10.1007/bf00688687 · Cited by 25
Reciprocal Changes in Psychosis and Mood After Physostigmine in a Patient With Alzheimer's Disease
Vitiello, B. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810360077011 · Cited by 9
Cited by
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
Impact of Anticholinergics on the Aging Brain: A Review and Practical Application
Boustani, M., Campbell, N., Munger, S., Maidment, I., & Fox, C. (2008) · Aging Health · doi:10.2217/1745509x.4.3.311 · Cited by 862
Treatment of Alzheimer's disease; current status and new perspectives
scarpini, E., Schelterns, P., & Feldman, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00502-7 · Cited by 721
Keri, R. S., Patil, M. R., Patil, S. A., & Budagumpi, S. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.059 · Cited by 631
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579
Metadata
- Authors
- Cummings, J. L.
- Venue
- American Journal of Psychiatry
- Published
- 2000-01-01
- Volume
- 157
- Issue
- 1
- Pages
- 4-15
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2135093451
- Cited by
- 384
- References
- 88
- FWCI
- 24.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.